Invasive procedures can be performed safely in children with haemophilia due to the availability of factor VIII/IX for patients without inhibitors. Most guidelines are based on the experiences in adults, but still there is no established consensus on the optimal factor levels or duration of replacement therapy for adults undergoing surgery. Few publications have focused on surgery in children with haemophilia. Children who have developed inhibitors to factor VIII/IX have to be treated with bypassing agents and constitute a group at higher risk for bleeding complications during surgery. The aim of this review is to summarize the experiences and opinions in the literature on replacement treatment of children with haemophilia, with and without...
Replacement of the congenitally deficient factor VIII or IX through plasma-derived or recombinant co...
Introduction: Surgery is a risk factor for the development of factor VIII inhibiting antibodies (inh...
Introduction: Surgery is a risk factor for the development of factor VIII inhibiting antibodies (inh...
Although most surgical and invasive procedures can be performed safely in patients with haemophilia,...
INTRODUCTION Emicizumab (Hemlibra®, Hoffmann-La Roche, Switzerland) is now available for ...
Initiating prophylactic treatment at an early age is considered to be the optimal form of therapy fo...
The development of alloantibodies neutralising therapeutically administered factor (F) VIII/IX (inhi...
Data from prospective studies clearly demonstrate the efficacy of prophylactic treatment of haemophi...
The performance of surgery and invasive procedures in patients with haemophilia is currently facing ...
Hemophilia is the most common of the severe bleeding disorders and if not properly managed since ear...
PubMedID: 21519231Hemophilia patients sometimes need careful treatment of urgent serious bleedings a...
Replacement of the congenitally deficient factor VIII or IX through plasma-derived or recombinant co...
Aim: To assess available evidence on the use of rFVIIa in non-orthopaedic surgery including dental s...
Replacement of the congenitally deficient factor VIII or IX through plasma-derived or recombinant co...
Hemophilia is X-linked congenital coagulopathy. Patients with hemophilia need life-long substituted ...
Replacement of the congenitally deficient factor VIII or IX through plasma-derived or recombinant co...
Introduction: Surgery is a risk factor for the development of factor VIII inhibiting antibodies (inh...
Introduction: Surgery is a risk factor for the development of factor VIII inhibiting antibodies (inh...
Although most surgical and invasive procedures can be performed safely in patients with haemophilia,...
INTRODUCTION Emicizumab (Hemlibra®, Hoffmann-La Roche, Switzerland) is now available for ...
Initiating prophylactic treatment at an early age is considered to be the optimal form of therapy fo...
The development of alloantibodies neutralising therapeutically administered factor (F) VIII/IX (inhi...
Data from prospective studies clearly demonstrate the efficacy of prophylactic treatment of haemophi...
The performance of surgery and invasive procedures in patients with haemophilia is currently facing ...
Hemophilia is the most common of the severe bleeding disorders and if not properly managed since ear...
PubMedID: 21519231Hemophilia patients sometimes need careful treatment of urgent serious bleedings a...
Replacement of the congenitally deficient factor VIII or IX through plasma-derived or recombinant co...
Aim: To assess available evidence on the use of rFVIIa in non-orthopaedic surgery including dental s...
Replacement of the congenitally deficient factor VIII or IX through plasma-derived or recombinant co...
Hemophilia is X-linked congenital coagulopathy. Patients with hemophilia need life-long substituted ...
Replacement of the congenitally deficient factor VIII or IX through plasma-derived or recombinant co...
Introduction: Surgery is a risk factor for the development of factor VIII inhibiting antibodies (inh...
Introduction: Surgery is a risk factor for the development of factor VIII inhibiting antibodies (inh...